Supernus Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Supernus Pharmaceuticals generated cash of $111,085,000, which is less than the previous year. Cash used in financing activities reached the amount of -$397,880,000 last year. Net change in cash is therefore -$18,066,000.
Cash Flow
| 2014 | 7.73M | -4.88M | 570K |
|---|---|---|---|
| 2015 | 32.12M | -36.23M | 1.86M |
| 2016 | 66.81M | -35.96M | 2.05M |
| 2017 | 114.64M | -86.41M | 5.68M |
| 2018 | 128.98M | -413.48M | 376.43M |
| 2019 | 143.12M | -157.92M | 3.92M |
| 2020 | 138.39M | -34.69M | 3.55M |
| 2021 | 127.12M | -81.91M | -130.42M |
| 2022 | 116.82M | -216.66M | -10.47M |
| 2023 | 111.08M | 268.72M | -397.88M |
SUPN Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 93.12M | 203.43M | 288.64M | 181.38M | 192.24M | 100.30M | 66.39M | 33.49M | 36.39M | 32.98M |
Operating activities | ||||||||||
Net income | 1.31M | 60.71M | 53.42M | 126.95M | 113.05M | 110.99M | 57.28M | 91.22M | 14.01M | 19.87M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 84.85M | 85.54M | 32.59M | 18.14M | 6.65M | 7.06M | 8.13M | 2.39M | 921K | 928K |
Stock-based compensation expense | 26.75M | 17.56M | 17.91M | 16.56M | 14.84M | 0 | 8.43M | 5.92M | 4.23M | 2.71M |
| Deferred income tax benefit | 26.75M | 17.56M | 17.91M | 16.56M | 14.84M | 0 | 8.43M | 5.92M | 4.23M | 2.71M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 18.76M | -16.36M | 3.86M | -34.60M | 15.75M | -35.85M | -24.05M | -15.61M | -8.63M | -12.21M |
Inventories | 6.11M | -17.85M | -14.58M | -10.12M | -969K | -9.35M | 497K | -4.21M | 854K | -6.28M |
Accounts payable | -36.28M | -19.16M | 18.17M | 8.27M | 6.96M | -3.57M | -620K | 3.47M | 2.06M | -1.27M |
Cash generated by operating activities | 111.08M | 116.82M | 127.12M | 138.39M | 143.12M | 128.98M | 114.64M | 66.81M | 32.12M | 7.73M |
Investing activities | ||||||||||
Purchases Of Investments | -101.62M | -406.99M | -311.57M | -95.89M | -409.70M | -491.65M | -101.88M | -47.36M | -63.20M | -53.26M |
Investments In Property Plant And Equipment | -551K | -412K | -2.04M | -3.44M | -2.73M | -844K | -2.02M | -1.60M | -2.10M | -593K |
Acquisitions Net | 0 | -14K | -311.69M | -313.54M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 268.72M | -216.66M | -81.91M | -34.69M | -157.92M | -413.48M | -86.41M | -35.96M | -36.23M | -4.88M |
Financing activities | ||||||||||
Common Stock Issued | 6.61M | 12.42M | 7.09M | 4.36M | 3.92M | 11.58M | 5.68M | 2.05M | 1.86M | 571K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -402.5M | 0 | -138.31M | -802K | 0 | -299.16M | 0 | 0 | 0 | 0 |
Cash used in financing activities | -397.88M | -10.47M | -130.42M | 3.55M | 3.92M | 376.43M | 5.68M | 2.05M | 1.86M | 570K |
Net Change In Cash | -18.06M | -110.31M | -85.20M | 107.25M | -10.86M | 91.94M | 33.90M | 32.9M | -2.24M | 3.41M |
Cash at end of period | 75.05M | 93.12M | 203.43M | 288.64M | 181.38M | 192.24M | 100.30M | 66.39M | 34.15M | 36.39M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |